These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 35296005)

  • 1. Efficacy and Safety of Radiofrequency Ablation vs. Endoscopic Surveillance for Barrett's Esophagus With Low-Grade Dysplasia: Meta-Analysis of Randomized Controlled Trials.
    Wang Y; Ma B; Yang S; Li W; Li P
    Front Oncol; 2022; 12():801940. PubMed ID: 35296005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Radiofrequency Ablation versus Endoscopic Surveillance for Barrett's Esophagus with Low-Grade Dysplasia: A Systematic Review and Meta-Analysis.
    Klair JS; Zafar Y; Nagra N; Murali AR; Jayaraj M; Singh D; Rustagi T; Krishnamoorthi R
    Dig Dis; 2021; 39(6):561-568. PubMed ID: 33503615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and durability of radiofrequency ablation for Barrett's Esophagus: systematic review and meta-analysis.
    Orman ES; Li N; Shaheen NJ
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1245-55. PubMed ID: 23644385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia.
    Small AJ; Araujo JL; Leggett CL; Mendelson AH; Agarwalla A; Abrams JA; Lightdale CJ; Wang TC; Iyer PG; Wang KK; Rustgi AK; Ginsberg GG; Forde KA; Gimotty PA; Lewis JD; Falk GW; Bewtra M
    Gastroenterology; 2015 Sep; 149(3):567-76.e3; quiz e13-4. PubMed ID: 25917785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost effectiveness of radiofrequency ablation for Barrett's esophagus.
    Hur C; Choi SE; Rubenstein JH; Kong CY; Nishioka NS; Provenzale DT; Inadomi JM
    Gastroenterology; 2012 Sep; 143(3):567-575. PubMed ID: 22626608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radio frequency ablation of dysplastic Barrett's esophagus: Outcomes of a single-center registry.
    Mathiesen M; Holm J; Thorsteinsson M
    Scand J Surg; 2023 Jun; 112(2):86-90. PubMed ID: 36756673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoscopic radiofrequency ablation or surveillance in patients with Barrett's oesophagus with confirmed low-grade dysplasia: a multicentre randomised trial.
    Barret M; Pioche M; Terris B; Ponchon T; Cholet F; Zerbib F; Chabrun E; Le Rhun M; Coron E; Giovannini M; Caillol F; Laugier R; Jacques J; Legros R; Boustiere C; Rahmi G; Metivier-Cesbron E; Vanbiervliet G; Bauret P; Escourrou J; Branche J; Jilet L; Abdoul H; Kaddour N; Leblanc S; Bensoussan M; Prat F; Chaussade S
    Gut; 2021 Jun; 70(6):1014-1022. PubMed ID: 33685969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
    Wani S; Rubenstein JH; Vieth M; Bergman J
    Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression from low-grade dysplasia to malignancy in patients with Barrett's esophagus diagnosed by two or more pathologists.
    Moole H; Patel J; Ahmed Z; Duvvuri A; Vennelaganti S; Moole V; Dharmapuri S; Boddireddy R; Yedama P; Bondalapati N; Uppu A; Vennelaganti P; Puli S
    World J Gastroenterol; 2016 Oct; 22(39):8831-8843. PubMed ID: 27818599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review and meta-analysis of the effectiveness of radiofrequency ablation in low grade dysplastic Barrett's esophagus.
    Pandey G; Mulla M; Lewis WG; Foliaki A; Chan DSY
    Endoscopy; 2018 Oct; 50(10):953-960. PubMed ID: 29689573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance After Treatment of Barrett's Esophagus Benefits Those With High-Grade Dysplasia or Intramucosal Cancer Most.
    Cotton CC; Shaheen NJ; Thrift AP
    Am J Gastroenterol; 2022 Jul; 117(7):1056-1062. PubMed ID: 35435856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage cryotherapy after failed radiofrequency ablation for Barrett's esophagus-related dysplasia is safe and effective.
    Sengupta N; Ketwaroo GA; Bak DM; Kedar V; Chuttani R; Berzin TM; Sawhney MS; Pleskow DK
    Gastrointest Endosc; 2015 Sep; 82(3):443-8. PubMed ID: 25887715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid nitrogen spray cryotherapy in Barrett's esophagus with high-grade dysplasia: long-term results.
    Gosain S; Mercer K; Twaddell WS; Uradomo L; Greenwald BD
    Gastrointest Endosc; 2013 Aug; 78(2):260-5. PubMed ID: 23622979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort.
    Song KY; Henn AJ; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
    Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31274147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett's esophagus-related neoplasia: a systematic review and pooled analysis.
    Desai M; Saligram S; Gupta N; Vennalaganti P; Bansal A; Choudhary A; Vennelaganti S; He J; Titi M; Maselli R; Qumseya B; Olyaee M; Waxman I; Repici A; Hassan C; Sharma P
    Gastrointest Endosc; 2017 Mar; 85(3):482-495.e4. PubMed ID: 27670227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
    Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
    Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent indefinite for dysplasia in Barrett's esophagus is a risk factor for dysplastic progression to low-grade dysplasia.
    Henn AJ; Song KY; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
    Dis Esophagus; 2020 Sep; 33(9):. PubMed ID: 32399569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiofrequency ablation for low-grade dysplasia in Barrett's esophagus: long-term outcome of a randomized trial.
    Pouw RE; Klaver E; Phoa KN; van Vilsteren FG; Weusten BL; Bisschops R; Schoon EJ; Pech O; Manner H; Ragunath K; Fernández-Sordo JO; Fullarton G; Di Pietro M; Januszewicz W; O'Toole D; Bergman JJ
    Gastrointest Endosc; 2020 Sep; 92(3):569-574. PubMed ID: 32217112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients With Barrett's Esophagus and Persistent Low-grade Dysplasia Have an Increased Risk for High-grade Dysplasia and Cancer.
    Kestens C; Offerhaus GJ; van Baal JW; Siersema PD
    Clin Gastroenterol Hepatol; 2016 Jul; 14(7):956-962.e1. PubMed ID: 26748222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.